# Mormil

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mormil

- Industry: Biotechnology
- Headquarters: Japan
- Website: www.molmir.co.jp
- Total disclosed funding: $2.6M
- Latest round: Series A (Apr 22, 2026)
- Investors on record: 7

## About

Established in 2022 and based in Japan, Mormil Co., Ltd., d.b.a. Mormil, engages in developing a drug discovery platform by observing the movement of molecules. In April 2026, Mormil Co., Ltd. raised JPY 300 million in series A funding from BP Capital, Nanto Capital Partners, Higin Capital, UntroD Capital, Mitsubishi UFJ Capital, and Senshu Ikeda Capital.

The company offers a core drug discovery technology platform that combines a chemical tongue with NMR (Nuclear Magnetic Resonance), a sensing technique that detects the movement and condition of molecules.

As of April 2026, the company plans to expand drug discovery pipelines, advance molecular dynamics platforms, progress ALS and AVWS programs, initiate clinical trials, strengthen pharmaceutical partnerships for commercialization, and global expansion.

## Funding rounds

- Series A, Apr 22, 2026, $1.9M — Mitsubishi UFJ Capital, Senshu Ikeda Capital, UntroD Capital Japan, Higin Capital, Nanto Capital Partners, BP Capital
- Seed, May 24, 2024, $0.8M — Mitsubishi UFJ Capital, Senshu Ikeda Capital, UntroD Capital

## Investors

- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Seed, Series A
- Senshu Ikeda Capital (https://capitalatlas.ai/funds/senshu-ikeda-capital) — Seed, Series A
- UntroD Capital — Seed
- UntroD Capital Japan (https://capitalatlas.ai/funds/untrod-capital-japan) — Series A
- Higin Capital (https://capitalatlas.ai/funds/higin-capital) — Series A
- Nanto Capital Partners (https://capitalatlas.ai/funds/nanto-capital-partners) — Series A
- BP Capital — Series A